Effect of valproate on cerebral metabolism and blood flow: An 18F-2-deoxyglusose and 15O water positron emission tomography study

William D. Gaillard, Thomas Zeffiro, Shahin Fazilat, Charles DeCarli, William H. Theodore

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

We compared the effect of valproate (VPA) on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF), measured with 18F-2-deoxyglucose (18FDG) and 15O water positron emission tomography (PET), in 10 normal volunteers. Mean VPA dose was 17.7 mg/ks, and mean VPA level was 82.1 mg/L (±16.5) for 4 weeks. VPA reduced global CMRGlc by 9.4% (9.60 ± 0.76 vs. 8.59 ± 1.02 mg Glc/min/100 g. p < 0.05) and regionally in all anatomic areas (p < 0.05 for 11 of 26 areas). VPA diminished global CBF by 14.9% (56.55 ± 6.70 vs. 47.48 ± 4.42 ml/min/100 g, p < 0.002) and regionally in all anatomic areas (p < 0.05 for 12 of 26 areas). No significant correlation was noted between VPA level and either global CMRGlc or CBF. The effect of VPA on global CMRGlc is similar to that of carbamazepine (CBZ) and phenytoin but less than that of phenobarbital, valium, or combination therapy with VPA and CBZ. VPA reduced regional CBF (rCBF) but not CMRGlc in the thalamus, an effect that may be associated with VPA's mechanism of action against generalized seizures.

Original languageEnglish (US)
Pages (from-to)515-521
Number of pages7
JournalEpilepsia
Volume37
Issue number6
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Valproic Acid
Positron-Emission Tomography
Water
Glucose
Carbamazepine
Regional Blood Flow
Deoxyglucose
Phenytoin
Phenobarbital
Diazepam
Thalamus
Healthy Volunteers
Seizures

Keywords

  • Cerebral blood flow
  • Cerebral metabolism
  • Positron emission tomography
  • Valproate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Effect of valproate on cerebral metabolism and blood flow : An 18F-2-deoxyglusose and 15O water positron emission tomography study. / Gaillard, William D.; Zeffiro, Thomas; Fazilat, Shahin; DeCarli, Charles; Theodore, William H.

In: Epilepsia, Vol. 37, No. 6, 06.1996, p. 515-521.

Research output: Contribution to journalArticle

Gaillard, William D. ; Zeffiro, Thomas ; Fazilat, Shahin ; DeCarli, Charles ; Theodore, William H. / Effect of valproate on cerebral metabolism and blood flow : An 18F-2-deoxyglusose and 15O water positron emission tomography study. In: Epilepsia. 1996 ; Vol. 37, No. 6. pp. 515-521.
@article{71a6fa42d02e43f8981fb1ba58e4e641,
title = "Effect of valproate on cerebral metabolism and blood flow: An 18F-2-deoxyglusose and 15O water positron emission tomography study",
abstract = "We compared the effect of valproate (VPA) on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF), measured with 18F-2-deoxyglucose (18FDG) and 15O water positron emission tomography (PET), in 10 normal volunteers. Mean VPA dose was 17.7 mg/ks, and mean VPA level was 82.1 mg/L (±16.5) for 4 weeks. VPA reduced global CMRGlc by 9.4{\%} (9.60 ± 0.76 vs. 8.59 ± 1.02 mg Glc/min/100 g. p < 0.05) and regionally in all anatomic areas (p < 0.05 for 11 of 26 areas). VPA diminished global CBF by 14.9{\%} (56.55 ± 6.70 vs. 47.48 ± 4.42 ml/min/100 g, p < 0.002) and regionally in all anatomic areas (p < 0.05 for 12 of 26 areas). No significant correlation was noted between VPA level and either global CMRGlc or CBF. The effect of VPA on global CMRGlc is similar to that of carbamazepine (CBZ) and phenytoin but less than that of phenobarbital, valium, or combination therapy with VPA and CBZ. VPA reduced regional CBF (rCBF) but not CMRGlc in the thalamus, an effect that may be associated with VPA's mechanism of action against generalized seizures.",
keywords = "Cerebral blood flow, Cerebral metabolism, Positron emission tomography, Valproate",
author = "Gaillard, {William D.} and Thomas Zeffiro and Shahin Fazilat and Charles DeCarli and Theodore, {William H.}",
year = "1996",
month = "6",
language = "English (US)",
volume = "37",
pages = "515--521",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of valproate on cerebral metabolism and blood flow

T2 - An 18F-2-deoxyglusose and 15O water positron emission tomography study

AU - Gaillard, William D.

AU - Zeffiro, Thomas

AU - Fazilat, Shahin

AU - DeCarli, Charles

AU - Theodore, William H.

PY - 1996/6

Y1 - 1996/6

N2 - We compared the effect of valproate (VPA) on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF), measured with 18F-2-deoxyglucose (18FDG) and 15O water positron emission tomography (PET), in 10 normal volunteers. Mean VPA dose was 17.7 mg/ks, and mean VPA level was 82.1 mg/L (±16.5) for 4 weeks. VPA reduced global CMRGlc by 9.4% (9.60 ± 0.76 vs. 8.59 ± 1.02 mg Glc/min/100 g. p < 0.05) and regionally in all anatomic areas (p < 0.05 for 11 of 26 areas). VPA diminished global CBF by 14.9% (56.55 ± 6.70 vs. 47.48 ± 4.42 ml/min/100 g, p < 0.002) and regionally in all anatomic areas (p < 0.05 for 12 of 26 areas). No significant correlation was noted between VPA level and either global CMRGlc or CBF. The effect of VPA on global CMRGlc is similar to that of carbamazepine (CBZ) and phenytoin but less than that of phenobarbital, valium, or combination therapy with VPA and CBZ. VPA reduced regional CBF (rCBF) but not CMRGlc in the thalamus, an effect that may be associated with VPA's mechanism of action against generalized seizures.

AB - We compared the effect of valproate (VPA) on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF), measured with 18F-2-deoxyglucose (18FDG) and 15O water positron emission tomography (PET), in 10 normal volunteers. Mean VPA dose was 17.7 mg/ks, and mean VPA level was 82.1 mg/L (±16.5) for 4 weeks. VPA reduced global CMRGlc by 9.4% (9.60 ± 0.76 vs. 8.59 ± 1.02 mg Glc/min/100 g. p < 0.05) and regionally in all anatomic areas (p < 0.05 for 11 of 26 areas). VPA diminished global CBF by 14.9% (56.55 ± 6.70 vs. 47.48 ± 4.42 ml/min/100 g, p < 0.002) and regionally in all anatomic areas (p < 0.05 for 12 of 26 areas). No significant correlation was noted between VPA level and either global CMRGlc or CBF. The effect of VPA on global CMRGlc is similar to that of carbamazepine (CBZ) and phenytoin but less than that of phenobarbital, valium, or combination therapy with VPA and CBZ. VPA reduced regional CBF (rCBF) but not CMRGlc in the thalamus, an effect that may be associated with VPA's mechanism of action against generalized seizures.

KW - Cerebral blood flow

KW - Cerebral metabolism

KW - Positron emission tomography

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0029996597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029996597&partnerID=8YFLogxK

M3 - Article

C2 - 8641226

AN - SCOPUS:0029996597

VL - 37

SP - 515

EP - 521

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 6

ER -